R 022335Z APR 21
MSGID/GENADMIN/CMC WASHINGTON DC PPO//
SUBJ/U.S. MARINE CORPS GUIDANCE FOR DEPLOYMENT AND REDEPLOYMENT OF INDIVIDUALS AND UNITS TESTING DURING THE NOVEL CORONAVIRUS DISEASE 2019 (COVID-19) PANDEMIC//
NARR/REF A IS UNDER SECRETARY OF DEFENSE FOR PERSONNEL AND READINESS(USD(P&R)) MEMORANDUM, FORCE HEALTH PROTECTION GUIDANCE (SUPPLEMENT 16)-DEPARTMENT OF DEFENSE GUIDANCE FOR DEPLOYMENT AND REDEPLOYMENT OF INDIVIDUALS AND UNITS DURING THE NOVEL CORONAVIRUS DISEASE 2019 PANDEMIC. REF B IS USD(P&R) MEMORANDUM, FORCE HEALTH PROTECTION (SUPPLEMENT 11)-DEPARTMENT OF DEFENSE GUIDANCE FOR CORONAVIRUS DISEASE 2019 SURVEILLANCE AND SCREENING WITH TESTING. REF C IS USD (P&R) MEMORANDUM, FORCE HEALTH PROTECTION GUIDANCE (SUPPLEMENT 15) REVISION 1-DEPARTMENT OF DEFENSE GUIDANCE FOR CORONAVIRUS DISEASE 2019 CLINICAL LABORATORY DIAGNOSTIC TESTING SERVICES. REF D IS MARADMIN 353/20 [PCRC1] (U.S. MARINE CORPS GUIDANCE FOR DEPLOYMENT AND REDEPLOYMENT OF INDIVIDUALS AND UNITS, SURVEILLANCE AND SCREENING AND TESTING, AS WELL AS LABORATORY DIAGNOSTIC TESTING DURING THE NOVEL CORONAVIRUS DISEASE 2019 PANDEMIC). REF E IS MARADMIN 537[PCRC2]/20 (SUPPLEMENTAL U.S. MARINE CORPS GUIDANCE FOR DEPLOYMENT AND REDEPLOYMENT OF INDIVIDUALS AND UNITS, SURVEILLANCE AND SCREENING AND TESTING, AS WELL AS LABORATORY DIAGNOSTIC TESTING DURING THE NOVEL CORONAVIRUS DIEASE 2019 PANDEMIC). REF F IS DOD COVID-19 TASK FORCE MEMORANDUM, DOD COVID-19 TASK FORCE LABORATORY TESTING LINE OF EFFORT. REF G IS DODI 6490.03,DEPLOYMENT HEALTH. REF H IS USD(P&R) MEMORANDUM, FORCE HEALTH PROTECTION GUIDANCE (SUPPLEMENT 18)-DEPARTMENT OF DEFENSE GUIDANCE FOR PROTECTING ALL PERSONNEL IN DEFENSE WORKPLACES DURING THE CORONAVIRUS DISEASE 2019 PANDEMIC. REF I IS USD (P&R) MEMORANDUM, FORCE HEALTH PROTECTION GUIDANCE (SUPPLEMENT 21) DEPARTMENT OF DEFENSE GUIDANCE FOR MOVEMENT AND MEDICAL TREATMENT OF COVID-19 PATIENTS, SYMPTOMATIC PERSONS UNDER INVESTIGATIN, OR POTENTIALLY EXPOSED COVID-19 PERSONS.//
POC/HQMC MARINE CORPS COVID CELL (MCCC) OPERATIONS OFFICER/UNIT: PP&O POC/F/TEL: (703) 692-4302/NIPR EMAIL: SMB_HQMC_MCCAT@USMC.MIL//
GENTEXT/REMARKS/1. This MARADMIN provides Service-level guidance for the implementation of reference (a) and directs compliance with references (b) and (c).
1. Background. This MARADMIN replaces reference (d) and reference (e).
2. Mission. The Marine Corps will implement the guidance provided in reference (a) through reference (c) to protect the force while executing our assigned mission.
3.A. Commander’s Intent.
3.A.1. Purpose. To promulgate updated Commandant of the Marine Corps (CMC) guidance for deployment, redeployment and testing during he COVID-19 pandemic.
3.A.2. Method. The Marine Corps will take steps to protect all Marines, Sailors, dependents, government civilians, and contract worker personnel, informed by Office of the Secretary of Defense (OSD) and Department of the Navy (DON) guidance.
3.A.3. End State. The Marine Corps mitigates, contains, and recovers from the effects of this public health challenge without interruption of our assigned mission.
3.B. Concept of Operations. The Marine Corps will comply with the requirements of deploying and redeploying individuals and units during the COVID-19 Pandemic as required in reference (a) through reference (c).
3.C.1. Screening and Testing.
3.C.1.a. Deploying forces will comply with the Electronic Foreign Clearance Guide (EFCG) including any EFCG requirements related toCOVID-19 pertaining to entry, movement, or operations into a host nation (HN). At a minimum, all personnel deploying outside the United States or redeploying to the United States will be tested with a viral test collected 1-3 days before departure, via commercial or military airlift. If the destination location requires a specific test or test timing, personnel must comply with that requirement, while still ensuring all personnel test prior to departure. Personnel are required to maintain proof of negative COVID-19 test during travel.
3.C.1.b. Individuals fully recovered from a laboratory-confirmed diagnosis of COVID-19 infection within the 90 days prior to scheduled deployment or redeployment are not required to undergo viral testing. Individuals are required to maintain documentation of recovery from COVID-19 during travel.
3.C.1.c. Waivers for pre-deployment testing, and exceptions for redeployment testing are available for limited circumstances in accordance with reference (a).
3.C.1.d. All Marine Corps units will ensure that deploying and redeploying Marines, Sailors, and civilian employees are appropriately screened for COVID-19 exposure. At a minimum, this screening will consist of an assessment of immunization (vaccination) status and date of series completion; any prior COVID-19 disease within the last 90 days and exposure history; a temperature check; a check for COVID-19 signs and symptoms (e.g., fever, chills, rigors, muscle pain, headache, sore throat, changes in smell or taste, coughing, or shortness of breath), and a review of any past COVID-19 test results.
3.C.1.e. A DoD healthcare provider will be available for consultation if unable to directly administer the screening.
3.C.1.f. All deploying and redeploying Marines, Sailors, and government civilian employees will complete Force Health Protection (FHP) pre-deployment requirements in accordance with reference (g).
3.C.1.g. All redeploying Marines, Sailors, and government civilian employees will complete a Post-Deployment Health Assessment (DD Form2796) and Post-Deployment Health Reassessment (DD Form 2900) in accordance with reference (g).
3.C.2. Restriction of Movement (ROM).
3.C.2.a. DEPLOYMENT REQUIREMENT: All Service members, civilian employees and contractors deploying outside the United States will undergo a mandatory 14-day ROM prior to deployment, except when a host nation requires a ROM upon arrival.
3.C.2.a.1. DEPLOYMENT ROM WAIVER AUTHORITY: Operational units can request a ROM waiver if mission requirements dictate an expedited deployment. The approval authority for a ROM waiver is the Secretary of Defense. ROM waiver requests should be routed through the Marine Corps COVID Cell (MCCC).
3.C.2.b. REDEPLOYMENT REQUIREMENT: All Service members, civilian employees and contractors redeploying from, or through, a foreign country will, upon arrival at their destination domicile, conduct a 14-day ROM.
3.C.2.c. ADDITIONAL DEPLOYMENT AND REDEPLOYMENT GUIDELINES.
3.C.2.c.1. ROM REDUCTION AUTHORITY: In accordance with guidance from the Secretary of the Navy, the authority to, after an appropriate risk assessment and if host nation agreements allow, decrease ROM to 10 days without testing, or 7 days with a negative viral test within 48 hours prior to the end of ROM, is delegated to the first General Officer/Flag Officer (GO/FO) or Senior Executive Service member (SES) or equivalent in a member’s chain of command.
3.C.2.c.2. DUAL-USE TEST: If ROM is completed prior to travel, tests completed to reduce ROM to 7 days meet the paragraph 3.C.1.a. Pre-flight testing requirement, provided the test is conducted 1-3 days before departure.
3.C.2.c.3. SHIPBOARD ROM: For shipboard deployments: underway time from port of embarkation/debarkation to port of debarkation/embarkation may be used to meet ROM requirements provided no cases of COVID-19 have occurred while underway and no contact that would permit transmission of the virus has occurred with other vessels.
3.C.2.c.4. CONUS DEPLOYMENTS: For deployments which take place entirely within the continental United States, individuals will undergo a risk-based screening to determine if a ROM is required for deployment or redeployment. If required, ROM will be conducted in accordance with reference (a).
3.C.2.c.5. INDIVIDUAL AUGMENTS: For individual augments (IAs), coordination for ROM requirements, in accordance with screening criteria in reference (a), will be directed by M&RA and coordinated by respective MARFORs or parent commands.
3.C.2.c.6. ROM LOCATIONS: ROM locations for units and individuals will be coordinated with the losing and gaining organizations.
3.C.2.d. RESERVE CONSIDERATIONS
3.C.2.d.1. Reserve Marines will perform any required ROM immediately upon return from deployments outside of the United States at the return intermediate location (RILOC) or Home Training Center for self-RILOCing units, prior to completion of orders.
3.C.2.d.2. Reserve Marines in support of another Department or Agency will complete any required health and ROM measures, including home-based quarantine or self-monitoring, while on orders both initially and prior to the end of the period of support to that other Department or Agency.
3.C.2.e. ESSENTIAL PERSONNEL: The first General Officer/Flag Officer (GO/FO) or Senior Executive Service member (SES) or equivalent in a member’s chain of command may grant an exception to ROM requirements for personnel who have redeployed to home station and whose presence is required in the DoD workplace, provided a health risk assessment is completed, they remain asymptomatic, wear a face covering and practice social distancing in accordance with reference (h).
3.C.2.f. Additional ROM guidance may be found in reference (a).
3.C.3. Additional Requirements.
3.C.3.a. VACCINE STATUS: Service members and government civilian employees and contractors will follow CDC travel guidelines for fully vaccinated individuals.
3.C.3.b. Travel to deployment locations should, to the maximum extent possible, minimize the risk of deploying Marines, Sailors, and government civilian employees of being exposed to or infected with COVID-19.
3.C.3.c. Contact tracing is required on all confirmed COVID-19 cases in accordance with reference (c).
3.C.3.d. Symptomatic, probable, or confirmed COVID-19 Marines, Sailors, and government civilian employees will be isolated and their movement limited in accordance with reference (a), reference (c) and current CDC guidance.
3.C.3.e. All contracts that include performance outside the United States will require DoD contractor personnel to comply with the country entry requirements of the respective GCC (which include screening, ROM, and testing), as reflected in the EFCG, and all applicable host nation procedures.
3.C.3.f. MEDICAL TRANSPORT: Medical care will not be delayed due to ROM or testing requirements. Patients and their attendants in the en-route care system are exempt from ROM requirements and may be exempted from testing requirements by the Theater Validating Flight Surgeon until they arrive at their final treatment destination.
3.C.3.g. Units are directed to capture expenses related to ROM and
other COVID-19 costs using special interest code NB0 (NOVEMBER-BRAVO-ZERO).
3.C.4. Other Testing Programs.
3.C.4.a. The Marine Corps will conduct testing in accordance with reference (b) and reference (c).
3.C.4.b. Units will continue reporting selected test requirements as directed by MCCC.
4. Administration and Logistics.
4.A.1 Force Health Protection Guidance: https:(slash)(slash)www.defense.gov/Explore/Spotlight/Coronavirus/.
4.A.2. Electronic Foreign Clearance Guide: https:(slash)(slash)www.fcg.pentagon.mil/fcg.cfm
4.A.3. CDC Travel Health Notices: https:(slash)(slash)www.cdc.gov/travel/notices
5. Command and Signal
5.A. This MARADMIN has been coordinated with HQMC, Health Services, HQMC Judge Advocate Division, Communication Directorate, DC AVN, DC CD&I, DC I, DC I&L, DC M&RA, DC P&R, MCICOM, and Office of Legislative Affairs.
5.B. This MARADMIN applies to the Total Force and is effective upon release.
5.C. This message is approved for release by LtGen G. W. Smith, Jr. Deputy Commandant, Plans, Policies, and Operations.//